AKT1 and hepatocellular carcinoma: This preparation showed stronger antitumor activity in both cell experiments and an AKT/c-Met-induced HCC mouse model, which also indicated that this drug delivery system is an effective carrier for the delivery of anti-hepatoma drugs.